文献速递肿瘤 PET/CT核素与放射性配体治疗

基于患者内与患者间分析的[68Ga]Ga-PSMA-11与[18F]F-PSMA-1007 PET/CT生物分布评估

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis.
PubMed 文献 · EJNMMI Res · 2024-04-05

纳入两个中心一年内同时接受[18F]F-PSMA-1007与[68Ga]Ga-PSMA-11 PET检查的50例患者,比较肝脏、脾脏、唾液腺、血池和骨的SUVmean及病灶摄取。结果[18F]F-PSMA-1007的肝脏SUVmean(11.7±3.9)与脾脏SUVmean(11.2±3.5)均显著高于[68Ga]Ga-PSMA-11(肝脏5.4±1.7、脾脏8.1±3.5,p<.05),血池两者相当,恶性病灶未见[18F]F-PSMA-1007 SUVmean更高。患者内肝脏摄取呈线性相关:SUVmean[68Ga]Ga-PSMA-11=0.33×SUVmean[18F]F-PSMA-1007+1.52(r=.78,p<.001)。

要点

  • [18F]F-PSMA-1007肝脏SUVmean 11.7±3.9,高于[68Ga]Ga-PSMA-11的5.4±1.7(p<.05)。
  • [18F]F-PSMA-1007脾脏SUVmean 11.2±3.5,高于[68Ga]Ga-PSMA-11的8.1±3.5(p<.05)。
  • 两示踪剂患者内肝脏摄取线性相关,r=.78(p<.001)。

核心结论

  • 比较[68Ga]Ga与[18F]F示踪剂的生物分布,[68Ga]Ga-PSMA-11 PET的肝脏摄取是最稳健的内部参考值。
  • [18F]F-PSMA-1007的肝脏摄取显著更高,脾脏摄取也显著更高。
  • 两种扫描间肝脏积聚的强患者内关联可能允许使用转换因子,以[18F]F-PSMA-1007为基础进行放射性配体治疗筛选。

研究设计与样本

  • 纳入两个中心一年内同时接受[18F]F-PSMA-1007与[68Ga]Ga-PSMA-11 PET检查的50例患者。
  • 获取肝脏、脾脏、唾液腺、血池和骨的SUVmean,并评估原发肿瘤、局部复发、淋巴结、骨或内脏转移,进行患者内与患者间比较。

主要发现

  • [18F]F-PSMA-1007肝脏SUVmean为11.7±3.9,[68Ga]Ga-PSMA-11为5.4±1.7(p<.05)。
  • [18F]F-PSMA-1007脾脏SUVmean为11.2±3.5,[68Ga]Ga-PSMA-11为8.1±3.5(p<.05)。
  • 两种扫描间血池相当。
  • 恶性病灶在[18F]F-PSMA-1007上未显示更高的SUVmean。
  • 患者内肝脏摄取线性关联:SUVmean[68Ga]Ga-PSMA-11=0.33×SUVmean[18F]F-PSMA-1007+1.52(r=.78,p<.001)。

关键数值与推荐

  • [18F]F-PSMA-1007肝脏SUVmean 11.7±3.9 vs [68Ga]Ga-PSMA-11 5.4±1.7(p<.05)。
  • [18F]F-PSMA-1007脾脏SUVmean 11.2±3.5 vs [68Ga]Ga-PSMA-11 8.1±3.5(p<.05)。
  • 患者内肝脏摄取线性方程:SUVmean[68Ga]Ga-PSMA-11=0.33×SUVmean[18F]F-PSMA-1007+1.52(r=.78,p<.001)。

临床怎么用

  • [68Ga]Ga-PSMA-11 PET的肝脏摄取被用作内部参考值,结合临床参数筛选[177Lu]Lu-PSMA-617放射性配体治疗患者。
  • 作者认为,两种扫描间肝脏积聚的强患者内关联可能允许使用转换因子,以[18F]F-PSMA-1007为基础进行放射性配体治疗筛选。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver uptake in [68Ga]Ga-PSMA-11 PET is used as an internal reference in addition to clinical parameters to select patients for [177Lu]Lu-PSMA-617 radioligand therapy (RLT). Due to increased demand, [68Ga]Ga-PSMA-11 was replaced by [18F]F-PSMA-1007, a more lipophilic tracer with different biodistribution and splenic uptake was suggested as a new internal reference. We compared the intra-patient tracer distribution between [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007. METHODS: Fifty patients who underwent PET examinations in two centers with both [18F]F-PSMA-1007 and [68Ga]Ga-PSMA-11 within one year were included. Mean standardized uptake values (SUVmean) were obtained for liver, spleen, salivary glands, blood pool, and bone. Primary tumor, local recurrence, lymph node, bone or visceral metastasis were also assessed for intra- and inter-individual comparison. RESULTS: Liver SUVmean was significantly higher with [18F]F-PSMA-1007 (11.7 ± 3.9) compared to [68Ga]Ga-PSMA-11 (5.4 ± 1.7, p < .05) as well as splenic SUVmean (11.2 ± 3.5 vs.8.1 ± 3.5, p < .05). The blood pool was comparable between the two scans. Malignant lesions did not show higher SUVmean on [18F]F-PSMA-1007. Intra-individual comparison of liver uptake between the two scans showed a linear association for liver uptake with SUVmean [68Ga]Ga-PSMA-11 = 0.33 x SUVmean [18F]F-PSMA-1007 + 1.52 (r = .78, p < .001). CONCLUSION: Comparing biodistribution of [68Ga]Ga and [18F]F tracers, liver uptake on [68Ga]Ga-PSMA-11 PET is the most robust internal reference value. Liver uptake of [18F]F-PSMA-1007 was significantly higher, but so was the splenic uptake. The strong intra-individual association of hepatic accumulation between the two scans may allow using of a conversion factor for [18F]F-PSMA-1007 as a basis for RLT selection.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Popescu CE, Zhang B, Sartoretti T, et al. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024. PMID: 38578516. doi:10.1186/s13550-024-01097-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。